IDS 6/24/03

•* •**	•	nside this box	are requir	ed to respond to a collection o	il information unless	it contains a valid OMF	3 control	number	Patent	Approved for use and Trademark Office:	PTC/SE se through 10/31/99. OM U.S. DEPARTMENT OF (	B/08A (10 1B 0651-0 COMMER
		ute for form 1449/							nplete	if Known		
JIP.		STATEME	NT E	DISCLOSU BY APPLICA		Application	Numb	er		10/053,929		
2 4 201	מ מ	(use as ma	ny sne	ets as necessary)		Filing Date				January 22, 2	2002	
£ 7 500						First Named	Invo	ntor		Julie Straub		
	AST					Group Art U		itoi		1617		
Mannet M						Examiner Na				1017		
Sheet	<u>-</u>	of		1		Attorney Do		lumber		ACU 109 CIP		
SHEEL		) 01				Attorney Do	CKELI	idilibei		HOO 103 011		_
					U.S. PATE	NT DOCUME	NTS				<del></del>	
Examiner Initials*	Cite No.	US Patent Docur	ment		atentee or Ap ited Documen	plicant		Date of Cited Document M-DD-YYYY	Pa F	iges, Columns, L assages or Rele	ines, Where Relev	vant ear
		(if I	Code <sup>2</sup> known)								·- · · · · · · · · · · · · · · · · · ·	
9		4,818,542		DeLuca, et al.			04-0	4-1989	<u> </u>			
170		6,565,885		Tarara, et al.			05-2	0-2003				
1												
7/									1		77	
							I			<u> </u>		
							↓		<u> </u>	6	111	
							<del>↓</del>		L	3-6	$\overline{}$	
							┼		ļ	TO Z	m	
							<del> </del>		<del>                                     </del>	<del>-3 *</del>		
							$\vdash$		<del> </del>	TO T	- Z	
							1		<del>                                     </del>	TED :	ट्र ना	
		-1-10-1-1					<b>1</b> .			9	8 111	
							<u> </u>	-	ļ	0		
							<u> </u>		<u> </u>	<u>~</u>		
		····		E	OBEIGN DA	TENT DOCUM	MENIT	e		<del>- 8</del>		
Examiner	Cite	Enraign	Dalent F			of Patentee or	41	Date of Publica	tion of	Panes Column	ns, Lines, Where	Т т
Initials*			fice. <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup>			of Cited Docume	ent -	Cited Documer DD-YYYY	nt MM-	Relevant Passa	iges or Relevant Appear	
				(if known)					<del>-  </del>			+-
									-			
											·	+
									$\dashv$			+-
		<del>                                     </del>							-		<del></del>	+
		<del>                                     </del>			· <del></del>							+

Date Considered

9/04

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Examine

Signature

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-96

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Substitute for form 1449A/PTO	Complete If Known		
INFORMATION DISCLOSURE OF ESTATEMENT BY APPLICANT Of the as many sheets as necessary)  JUN 1 9 2002 65	Application Number	10/053,929	
1 9 2002 0	Filing Date	January 22, 2002	
[ JUR , 5]	First Named Inventor	Julie Straub	
[\s_ &/	Group Art Unit		
Who will	Examiner Name		
Sheet TRADE of 12	Attorney Docket Number	ACU 109 CIP	

			U.S. PATENT DOCU	MENTS	
Examiner Initials*	Cite No.1	US Patent Document	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code 2 (if known)			COPY OF PAPERS
1		<del> </del>	Ecanow	01-17-1995	ORIGINALLY FILED
77		5,468,598	Miller et al.	11-21-1995	
4		5,470,583	Na, et al.	11-28-1995	
		5,500,331	Czekai, et al.	03-19-1996	
		5,510,118	Bosch, et al.	04-23-1996	מר (רווידוי)
		5,513,803	Czekai, et al.	05-07-1996	HEODIVE
		5,518,187	Bruno, et al.	05-21-1996	:
		5,518,738	Eickhoff, et al.	05-21-1996	U.N. 0.7 2002
7		5,534,270	De Castro	07-09-1996	JUN 2 7 2002
		5,552,160	Liverside et al.	09-03-1996	1
		5,560,932	Bagchi, et al.	10-01-1996	
		5,565,188	Wong, et al.	10-15-1996	TECH CENTER 1600/2000
		5,569,448	Wong, et al.	10-29-1996	12011 05
		5,571,536	Eickhoff, et al.	11-05-1996	
4		5,580,579	Ruddy, et al.	12-03-1996	1.16
7		5,587,143	Wong	12-24-1996	1 1000

Examiner Initials*	Cite No.1		Foreign Patent Doo	ument	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office.3	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	]	1		
<i>y</i>		CA	2 136 704		Hoechst Aktiengesellschaft	05-28-1995		
01		DE	37 13 326	A1	BASF AG	10-29-1987		1
T		EP	0 655 237	A1	Hoechst Aktiengesellschaft	05-31-1995	· · · · · · · · · · · · · · · · · · ·	1
T		GB	1 265 615		Boehringer Mannheim G.M.B.H.	03-01-1972	;	
		wo	99/56731	A1	Acusphere, Inc.	11-11-1999	:	

Examine	/ 4	Date Considered	9/,
Signature		]	7/04

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant to place a check mark here if English language Translation is attached.





Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-96 Approved for use through 10/31/99, OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1	
	_
Т	

Substitute for form 1449A/PTO	Complete if Known RECEIVED				
O PE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/053,929 JUN 2 7 2002 TECH CENTER 1600/			
JUH 1 9 July (Use as many sheets as necessary)	Filing Date	January 22, 2002			
	First Named Inventor	Julie Straub			
TRADEMARKS	Group Art Unit				
TRADEM	Examiner Name				
Sheet 2 of 12	Attorney Docket Number	ACU 109 CIP			

U.S. PATENT DOCUMENTS							
xaminer Initials*	Cite No.	US Patent	Document	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number	Kind Code <sup>2</sup> (if known)				
4		5,591,456		Franson, et al.	01-07-1997	<u>-</u>	
0		5,609,998		Texter, et al.	03-11-1997	RECEIVE	
		5,622,279		Czekai, et al.	09-02-1997		
		5,622,938		Wong	04-22-1997		
		5,657,931		Nair, et al.	08-19-1997	ILIN 9 7 2002	
		5,662,883		Bagchi, et al.	09-02-1997		
		5,665,331		Bagchi, et al.	09-09-1997		
		5,716,642		Bagchi, et al.	02-10-1998	TECH CENTER 1600, 2000	
7 7		5,718,919		Ruddy, et al.	02-17-1998	IEOH OEMIEN 1000/2000	
		5,747,001	14.	Wiedman, et al.	05-05-1998		
$\mathbf{I}^{-1}$		5,762,961		Roser et al.	06-09-1998	i je drugovija	
$T^{-1}$		5,919,434	100	Dugstad, et al.	07-06-1999	COPY OF PAPEL	
$L\Box$		5,976,574		Gordon, et al.	11-02-1999	ODYOMALLY EU EC	
$\tau_Z$		5,985,285		Titball, et al.	11-16-1999	OFHIGHNALLY FILED	
V		6,001,336		Gordon	12-14-1999	1 1000	

Examiner Initials*	Cite No.1	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office.3	Number	Kind Code <sup>5</sup> (if known)	5	1		
8,		wo	98/31346	A1	Massachusetts Institute of Technology	07-23-1998		
4		wo	98/51282	A1	Imarx Pharmaceutical Corp.	11-19-1998		
			L					

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+

Examine

Signature

04

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

PTO/\$B/08A (10-96 Approved for use through 10/31/99. OMB 0551-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO RECEIVE Complete if Known Application Number 10/053,929 THE ORMATION DISCLOSURE JUN 2 7 2002 ATEMENT BY APPLICANT many sheets as necessary) January 22, 200 Filing Date Julie Straub First Named Inventor Group Art Unit Examiner Name

				1=20	
heet	3	of	12	Attorney Docket Number	ACU 109 CIP
			OTHERAD	NON OUTCOM LITERATURE DO	NIMENTO
				T - NON PATENT LITERATURE DOC	
xaminer's	Cite		Include name of the au	thor (in CAPITAL LETTERS), title of the art	ticle (when appropriate), title of the
Initials*	No.1		item (book, magazine, jo	urnal, senal, symposium, catalog, etc.), dat	e, page(s), volume-issue number(s).
				publisher, city and/or country where pu	
		DEVENE 9 DE	PICE "Chamical disca		ition of suspensions of ibuprofen and sustained
1					
()	l r	elease ibuprofe	en-wax microspheres,".	J. Microencapsul. 14(3):357-77 (1997	).
1					
//	4	HN et al "En	hancement of bigavails	hility of ketoprofen using dry elivir as	a novel dosage form," Drug Dev. Ind. Pharm.
<b>'</b> .				billy of Actoprofer dailing dry clicil as	a novel desage form, Drag Dev. ma. 1 namm.
- 1	ľ	4(7):697-701 (	1996).		
1					
	1 4	KADE, et al., "	Influence of polyethyle	ne glycol 6000 and mannitol on the in	-vitro dissolution properties of nitrofurantoin by
.			echnique." Pharmazie.		
1 1	ľ	ic dispersion to	comique, i namazio.	41(12):043-31 (1300):	
j	<b>₽</b>	KBARIEH & T	AWASHI, "Morphic feat	tures of solid particles after micronization	tion in the fluid energy mill," Int. J. Pharm. 35:81-
l l	8	9 (1987).			, , , , , , , , , , , , , , , , , , , ,
		, .		. t. 44 - 2	1
<del></del> ,'		11541 -1 -1 41			
()	lβ	LLEN, et al., "I	Dissolution rates of con	costeroids utilizing sugar glass dispe	rsions," J. Pharm. Sci. 66(4):494-97 (1977).
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\			,	1.75	
q.					
		NSEL-ot-al-E	hamacoutical-Dogaco	Forme-and-Drug-Delivery-Systems-F	Ed.; (Williams & Wilkins 1995).
			manmaceoucar-bosage	-Points-and-brog-betwery-bystems; c	Co., (VVillaris-a-VVIKIIS-1999).
**			* *		
				Assistant Company	
	٥	PPEL & ZENT	NER, "Use of modified	ethylcellulose lattices for microporous	s coating of osmotic tablets," Pharm. Res.
( )		(5):600-04 (19			in the second
: 14z	ľ	(0).000 04 (10.	3.1).		[* · · ]
<u></u> Y					
11	<u>β</u>	RIAS, et al., "D	Dissolution properties a	nd in vivo behaviour of triamterene in	solid dispersions with polyethylene glycols."
ΨI	l F	Pharm. Acta. He	elv. 71(4):229-35 (1996	).	
1 1			, ,		
		DIAS at al. "T	he application of solid	dispersion technique with D magnital	to the improvement in oral absorption of
- 1					to the improvement in trai absorption of
1	្រ	iamterene," J.	Drug Target. 2(1):45-5	l (1994).	·
- 1 - 1					I
	Α	RTEAGA et a	Dissolution velocity	of different calcium preparations used	Lin the clinical field " Rev. Med. Chil
//		24(11):1325-3		The same of the sa	The disconnections, Nov. Wee. Offic.
7		z+(11).1323-34	) (1330).		
$\mathcal{F}$					<u></u>
[					,
aminer's				Date Co	nsidered Cr / cr(1
gnature			$( \wedge )$		1 // 64

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

> COPY OF PAPERS ORIGINALLY FILED

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE

## COPY OF PAPERS ORIGINALLY FILED

Application Number

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Compl te if Known

10/053,929

Please type a plus sign (+) inside this box →

Substitute for form 1449A/PTO

OHIGHNALLY FILED	
	Approved for use
	Patent and Trademark Office: U.

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

JUN 2 7 2002

ㅗ
Υ
•

\(\rac{1}{2}\)\(\rac{1}{2}\)	Sil	/IEM	ENT	BY APPLICANT neets as necessary)					
	(	Helenasi C	many sł	eets as necessary)			January 22, 2002 CEN	TED 16	anak
1	g 20002	Kar as		ioos as noossary,	Filing Date		January 22 2 202 UEN	IED W	'لاڪئيان
704 ,	• -	5			First Named Inventor		Julie Straub		
o,		8) 8)			Group Art Unit				
Chr.	. aRt	Z			Examiner Name		<del></del>		$\neg \neg$
Sheel TR	ADEN'S		of	12	Attorney Docket Number		ACU 109 CIP		-
<u> </u>		L			<u> </u>		<u> </u>		
				OTHER ART - I	NON PATENT LITERATURE	DOCUMENTS	<del></del>		
Examiner's Initials*	Cite No.1			item (book, magazine, journal	(in CAPITAL LETTERS), title of the little of	), date, page(s), volur			T
9		BADIGE 14:1059-		"Porogens in the preparat	tion of microporous hydrogels		hylene oxides)," <i>Biomater</i>	ials	
	F	BODME	ER & P	AERATAKUL, "Spherical a	gglomerates of water-insolub	ole drugs," J. Phan	m. Sci. 78(11):964-67 (19	39).	
				et al., "In vitro and in vivo e arm. Drug Dispos. 5(3):26	valuation of controlled-releas 1-72 (1984).	e and enteric-coa	led formulations of sodium	1 :	
		BUCKTO 1998).	N, et al	, "The effect of comminution	on technique on the surface o	energy of a powde	r," Int. J. Pharm. 47:121-2	8	
					f the dissolution rate of crysta acokinet. Spec No 3:379-84		destined to intramuscular		94 (MH) F- (MB) M-1 (MB) M-1 (
				ronization: a method of im :211-15 (1998).	proving the bioavailability of	poorly soluble drug	gs," Meth. Find Exp. Clin.	100	, <u>ale.</u> , 1
		CHEN & 52 (1998)		actors affecting zero-orde	r release kinetics of porous g	elatin capsules," L	Orug Dev. Ind. Pharm. 24(	6):557-	7.55
		CHEN & 24(11):10			ting sustained-release capsu	le of verapamil," D	rug. Dev. Ind. Pharm.		
				LMAN, "Oral absorption of Pharm. Sci. 59(7):937-42 (1	f griseofulvin in dogs: increas 1970).	ed absorption via	solid dispersion in polyeth	ylene	
		SHIOU &	RIEGE	LMAN, "Pharmaceutical ap	pplications of solid dispersion	systems," J. Phai	m. Sci. 60:1281-1302 (19	71).	
Examiners Signature					Date	e Considered	9/84		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.





Please type a plus sign (+) inside this box →

T+	
•	

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond Substitute for form 1449A/PTO	to a collection of information unless it contains a va	RECEIVED
00034440 101111 1443/01 10	С	omplete if Known
INFORMATION DISCLOSURE  OF ESTATEMENT BY APPLICANT	Application Number	10/053,929 JUN 2 7 2002
Quise as many sheets as necessary)		TECH CENTER 1600/2300
1 9 70 C	Filing Date	January 22, 2002
JUH 1 5 DEC 61	First Named Inventor	Julie Straub
k)	Group Art Unit	
Sheets TRIADENTS of 12	Examiner Name	
Sheek TRADENS of 12	Attorney Docket Number	ACU 109 CIP

		OTHER ART - NON PATENT LITERATURE DOCUMENTS
Examiner's Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the article (when appropriate).		
V		CHIOU, et al., "Enhancement of dissolution rates of poorly water-soluble drugs by crystallization in aqueous surfactant solutions I: Sulfathiazole, Prednisone, and Chloramphenicol," J. Pharm. Sci. 65:1702-04 (1976).
1		CHRISTENSEN, et al., "Storage of polyvinylpyrrolidone (PVP) in tissues following long-term treatment with a PVP-containing vasopressin preparation," Act. Med. Scand. 204:295-98 (1978).
		CORRIGAN & HOLOHAN, "Amorphous spray-dried hydroflumethiazide-polyvinylpyrrolidone systems: physiochemical properties," <i>J. Pharm. Pharmacol.</i> 36(4):217-21 (1984).
		DE ALMEIDA, et al., "Modeling dissolution of spanngly soluble multisized powders," J. Pharm. Sci. 86:726-732 (1997).
		DORDUNOO, et al., "Physical stability of solid dispersions containing triamterene or ternazepam in polyethylene glycols," <i>J. Pharm. Pharmacol.</i> 49(4):390-96 (1997).
ija. Pr		DRESSMAN & FLEISHER, "Mixing-tank model for predicting dissolution rate control or oral absorption," J. Pharm. Sci. 75(2):109-16 (1986).
1		EICHMAN & ROBINSON, "Mechanistic studies on effervescent-induced permeability enhancement," <i>Pharm. Res.</i> 15(6):925-30 (1998).
		EL-FATTAH, et al., "Enhancement of dissolution rate of hydrochlorothiazide via solid dispersion," <i>Pharmazie</i> . 41(11):790-93 (1986).
		FEINSTEIN & SCIARRA, "Development and evaluation of a dexamethasone timed-release aerosol formulation," J. Pharm. Sci. 64:408-13 (1975).
9/		FENIMORE & LOY, "Injectible dispersion of $\Delta^9$ -tetrahydrocannabinol in saline using polyvinyl pyrrolidone," <i>J. Pharm. Pharmac.</i> 23:310- (1971).
aminer's	<del></del>	[Date Considered]

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

┿

Signature

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.





Please type a plus sign (+) inside this box -

PTO/SB/0	8A (10-9
Approved for use through 10/31/99, OMB (	0651-003
Patent and Trademark Office: U.S. DEPARTMENT OF CO	MMERC

Substitute for form 1449A/PTO	Complete if Known RECEIVED			
INFORMATION DISCLOSURE P STATEMENT BY APPLICANT  (1) 2002 (1) as many sheets as necessary)	Application Number	10/053,929 JUN 2 7 2002 TECH CENTER 1600/2900		
JUN 1 9 ZDIZ 5	Filing Date	January 22, 2002		
300	First Named Inventor	Julie Straub		
<b>\3</b> , 3/	Group Art Unit			
Shoot TRADEMARK	Examiner Name			
Sheet 6 of 12	Attorney Docket Number	ACU 109 CIP		

Examiners	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	T²				
Initials*	No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	•				
9		FORD, "The current status of solid dispersions," Pharm. Act. Helv. 61:69-88 (1986).					
7		FREITAS & MÜLLER, "Spray-drying of solid lipid nanoparticles (SLN™)," Eur. J. Pharm. Biopharm. 46(2):145-51 (1998).					
		GALIA, et al., "Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs," Pharm. Res. 15(5):698-705 (1998).					
		GENTA, et al., "Improvement of dexamethasone dissolution rate from spray-dried chitosan microspheres," S.T.P. Pharma Sciences 5(3):202-07 (1995).					
		GHOSH, et al., "Product development studies on the tablet formulation of ibuprofen to improve bioavailability," <i>Drug Dev. Ind. Pharm.</i> 24(5):473-77 (1998).					
		GiUNCHEDI, et al., "A swellable polymer as carbamazepine dissolution rate enhancer," <i>Boll. Chim. Farm.</i> 129(1):17-20 (1990).					
		GRIJSEELS, et al., "Dissolution at porous interfaces VI: Multiple pore systems," J. Pharm. Sci. 73(12):1771-74 (1984).					
		GRIJSEELS, et al., "Dissolution at porous interfaces VI: Pore effects in natural convection flow," <i>Pharmaceutisch Weekblad Scienific Edition</i> 5:88-94 (1983).					
	•	HAMMAD & MÜLLER, "Increasing drug solubility by means of bile salt-phosphatidylcholine-based mixed micelles," Eur. J. Pharm. Biopharm. 46(3):361-67 (1998).					
Ø	,	HASTEDT & WRIGHT, "Diffusion in porous materials above the percolation threshold," <i>Pharm. Res.</i> 7(9):893-901 (1990).					
xaminers	1	Date Considered A 11V					

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to také 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

( · · · · ·
1 1997
200
V/
$\smile$



Please type a plus sign (+) inside this box  $\rightarrow$ 

	OURSHARLT FITED
+	

		P	TO/SB/08A (10-96
	Approved for use	through 10/31/99	OMB 0651-003
Patent and	Trademark Office: U.S	S. DEPARTMEN	T OF COMMERCE

Substitute for form 1449A/PTO	Co	omplete if Known RECEIVE
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/053,929 JUN 2 7 20n2
and (use as many sheets as necessary)		TECH CENTER 1000/L
JUN 1 9 2001 use as many sheets as necessary)	Filing Date	January 22, 2002
<u> </u>	First Named Inventor	Julie Straub
12 Oct Control of Cont	Group Art Unit	
E TRADENAST.	Examiner Name	

Examiner's I	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	T <sup>2</sup>
Initials*	No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	,
		HIRSCHBERG, et al., "Oral absorption of CGS-20625, an insoluble drug, in dogs and man," J. Pharmacokinet. Biopharm. 23(1):11-23 (1995).	
		HONG, et al., "Accelerated oral absorption of gliclazide in human subjects from a soft gelatin capsule containing a PEG 400 suspension of gliclazide," J. Controlled Release 51(2-3):185-92 (1998).	
		IMAI, et al., "Enhancement of the dissolution rates of poorly water-soluble drugs by water-soluble gelatin," Chem. Pharm. Bull. 37(8):2251-52 (1989).	
		IMAI, et al., "Rapidly absorbed solid oral formulations of ibuprofen using water-soluble gelatin," J. Pharm. Pharmacol. 42(9):615-19 (1990).	
	<del>-</del> .	JU, et al., "Drug release from hydrophilic matrices. 1. New scaling laws for predicting polymer and drug release based on the polymer disentanglement concentration and the diffusion layer," <i>J. Pharm. Sci.</i> 84(12):1455-63 (1995).	
		KAGKADIS, et al., "A freeze-dried injectable form of ibuprofen: development and optimisation using response surface methodology," PDA J. Pharm. Sci. Technol. 50(5):317-23 (1996).	,
		KAI, et al., "Oral absorption improvement of poorly soluble drug using solid dispersion technique," Chem. Pharm. Bull. 44(3):568-71 (1996).	1
		KANENIWA & WATARI, "Dissolution of slightly soluble drugs. I. Influence of particle size on dissolution behavior," Chem. Pharm. Bull. 22:1699-705 (1974).	
		KAUR, et al., "Comparison of polyethylene glycol and polyoxyethylene stearate as excipients for solid dispersion systems of griseofulvin and tolbutamide II: dissolution and solubility studies," <i>J. Pharm. Sci.</i> 69(11):1321-26 (1980).	
		KAWASHIMA, et al., "Improvement of solubility and dissolution rate of poorly water-soluble salicylic acid by a spray-drying technique," J. Pharm. Pharmacol. 27(1):1-5 (1975).	

Examiner's Signature	Date Considered	104
angination 1	1 9	-

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ATL1 #529035 v1

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.



## **COPY OF PAPERS**



Please type a plus sign (+) inside this box --

OMIGINALLY PLED	
	PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO		
		Complete if Known RECEIVED
INFORMATION DISCLOSURE	Application Number	10/053,929
STATEMENT BY APPLICANT  (Visit as many sheets as necessary)		JUN 2 7 2002
mm (1)	Filing Date	January 44-8842 CENTER 1600/20
اللا ع 2002 و ا	First Named Inventor	Julie Straub
.SJ	Group Art Unit	
(F) (S)	Examiner Name	
of 12	Attorney Docket Number	ACU 109 CIP

Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	T
		item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	•
		KHAN & JIABI, "Preparation, characterization, and dissolution studies of ibuprofen solid dispersions using polyethylene glycol (PEG), talc, and PEG-talc as dispersion carriers," <i>Drug Dev. Ind. Pharm.</i> 24(5):455-62 (1998).	
ſ		KHAN, et al., "Controlled release coprecipitates: formulation considerations," J. Control. Rel. 37:131-41 (1995)	-
		KIM & YOON, "Development of digoxin dry elixir as a novel dosage form using a spray-drying technique," J. Microencapsul. 12(5):547-56 (1995).	
		KINCL, et al., "Increasing oral bioavailability of progesterone by formulation," J. Steroid. Biochem. 9(1):83-84 (1978).	
		KONDO, et al., "Pharmacokinetics of a micronized, poorly water-soluble drug, HO-221, in experimental animals," <i>Biol. Pharm. Bull.</i> 16(8):796-800 (1993).	
		KUBO & MIZOBE, "Improvement of dissolution rate and oral bioavailability of a sparingly water-soluble drug, (+/-)-5-[[2-(2-naphthalenylmethyl)-5-benzoxazolyl]-methyl]- 2, 4-thiazolidinedione, in co-ground mixture with D-mannitol," <i>Biol. Pharm. Bull.</i> 20(4):460-63 (1997).	
		KUBO, et al., "Enhancement of oral bioavailability and pharmacological effect of 1-(3,4-dimethoxyphenyl)-2,3-bis(methoxycarbonyl)-4-hydroxy-6,7,8- trimethoxynaphthalene (TA-7552), a new hypocholesterolemic agent, by micronization in co-ground mixture with D-mannitol," <i>Biol. Pharm. Bull.</i> 19(5):741-47 (1996).	
		LEE, et al., "Mathematical modelling of the release of drug from porous, nonswelling transdermal drug-delivery devices," IMA J. Math. Appl. Med. Biol. 15(2):135-63 (1998).	
1		LEMOS-SENNA, et al., "Evaluation of the hydrophobic drug loading characteristics in nanoprecipitated amphiphillic cyclodextrin nanospheres," <i>Pharm. Dev. Tech.</i> 3:85-94 (1998).	_
8		LEUCUTA, et al., "The kinetics of nifefipine release from porous hydrophilic matrices and the pharmacokinetics in man,"  Pharmazie 43:845-48 (1988).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered Include copy of this form with next communication to applicant,

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ATL1 #529035 v1

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language





Please type a plus sign (+) inside this box --

-		
	+	1
- 1		

PTC/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO		Complete if Known RECEIVEL
INFORMATION DISCLOSURE PSEATEMENT BY APPLICANT  (USE as many sheets as necessary)	Application Number	JUN 2 7 2002
119 Day (1)	Filing Date	January 22, 2002 CENTER 1600/2
704 . E	First Named Inventor	Julie Straub
\ <b>\$</b> 67	Group Art Unit	
We made	Examiner Name	
heet of 12	Attorney Docket Number	ACU 109 CIP

Cunnaina.	Cit	OTHER ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	T²
itiluais	INO.	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
6		LIN, et al., "Improved oral absorption of L-365260, a poorly soluble drug," Biopharm. Drug Dispos. 17(1):1-15 (1996).	
		LIN, et al., "Preparation of enteric-coated microspheres of <i>Mycoplasma hyopneumoniae</i> vaccine with cellulose acetate phthalate: (II). Effect of temperature and pH on the stability and release behaviour of microspheres," <i>J. Microencapsul</i> . 8(4):537-45 (1991).	
		MARTINDALE, The Extra Pharmacopoeia, 711 Dissolution, pp. 1791-92, 30th Ed. (The Pharmaceutical Press, London 1993).	
		MASON & WINER, "Kinetics of aspirin, salicylic acid, and salicyluric acid following oral administration of aspirin as a tablet and two buffered solutions," <i>J. Pharm. Sci.</i> 70(3):262-65 (1981).	
		MIGLIARESI, et al., "Physical characterization of microporous poly(2-hydroxyethyl methacrylate) gels," J. Biomed. Mater. Res. 15:307-17 (1981).	
		MISHRA & YALKOWSKY, "A flat circular hole device for zero-order release of drugs: characterization of the moving dissolution boundary," <i>Pharm. Res.</i> 7(11):1195-97 (1990).	
		MORRIS, et al., "Structural properties of polyethylene glycol-polysorbate 80 mixture, a solid dispersion vehicle," <i>J. Pharm. Sci.</i> 81(12):1185-88 (1992).	
		NAJIB, et al., "The adsorption of hydrophilic polymers at the liquid-solid interface," J. Pharm. Pharmac. 29:43P (1977).	
		NISHIMURA, et al., "Dosage form design for improvement of bioavailability of levodopa VI: formulation of effervescent enteric-coated tablets," J. Pharm. Sci. 73(7):942-46 (1984).	
V		NYSTRÖM & WESTERBERG, "The use of ordered mixtures for improving the dissolution rate of low solubility compounds,"  J. Pharm. Pharmacol. 38(3):161-65 (1986).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

\_\_\_\_\_

Signature



INFORMATION DISCLOSURE

#### COPY OF PAPERS ORIGINALLY FILED

Application Number



Complete if Known

10/053,929

Please type a plus sign (+) inside this box →

Substitute for form 1449A/PTO

•	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	1	П		
۰	٦	۲	•	

STATEMENT BY APPLICA	NA I	
O TE (lose as many sheets as necessary)	Į	TECH CENTER 1600/
Coupe as many sneets as necessary)	Filing Date	January 22, 2002
111 1 9 2002 W	First Named Inventor	Julie Straub
JUH 1 0 LEE	Group Art Unit	
	Examiner Name	
\$\$69es	Attorney Docket Number	ACU 109 CIP
TRADEMA	- Filterinoy Doctor Hamilton	
OTHER A	RT - NON PATENT LITERATURE DOCL	JMENTS
	author (in CAPITAL LETTERS), title of the article, journal, serial, symposium, catalog, etc.), date, publisher, city and/or country where publisher.	page(s), volume-issue number(s),
NYSTRÖM, et al., "Dissolution rate n Pharm. Pharmacol. 37(4):217-21 (19	neasurements of sparingly soluble compo	ounds with the Coulter Counter model TAII," J.
OTSUKA, et al., "Hygroscopic stabilit Eudragit," J. Pharm. Sci. 82(1):32-38	ty and dissolution properties of spray-drie (1993).	d solid dispersions of furosemide with
PACE, et al., "Novel injectable formu	lations of insoluble drugs," Pharmaceutica	al Technology 116-34 (March 1999).
PILLAY & FASSIHI, "A new method in Pharm. Res. 16(2):333-37 (1999).	for dissolution studies of lipid-filled capsul	es employing nifedipine as a model drug,"
REDDY, et al., "Dissolution character 65(12):1753-58 (1976).	ristics and oral absorption of digitoxin and	digoxin coprecipitates," J. Pharm. Sci.
RIDOLFO, et al., "Benoxaprofen, a n in humans," J. Pharm. Sci. 68(7):850		effect on dissolution rate and oral absorption
SAANO, et al., "Relative pharmacoki Pharm. Ther. Toxic. 29:381-85 (1991		age forms in healthy volunteers," Int. J. Clin.
SCHRÖDER & SABEL, "Nanoparticle effects of i.v. dalargin injections," Bra	es, a drug carrier system to pass the bloo nin Research 710:121-24 (1996).	d-brain barrier, permit central analgesic
SERAJUDDIN, et al., "Effect of vehic from solid dispersions," J. Pharm. Sc		oavailability of a poorty water-soluble drug
SERAJUDDIN, et al., "Improved dissipolysorbate 80 mixtures," J. Pharm.		n solid dispersions in polyethylene glycol:
Examiner's Signature	Date Cons	idered a ly 4

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ATL1 #529035 v1

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.





Please-type a plus sign (+) inside this box

+	

Patent and Tradema

PTO/SB/08A (10-96	
toved for use through 10/31/99. OMB 0651-0031 rk Office: U.S. DEPARTMENT OF COMMERCE	4

Substitute for form 1449A/PTO		Complete if Known	RECEIVE
INFORMATION DISCLOSURE O PSE ATEMENT BY APPLICANT (George many sheets as necessary)	Application Number	10/053,929	JUN 2 7 2002
JUN 1 9 2002 W	Filing Date	January 22	GH&ENTER 180
JUN 1 - 2 3	First Named Inventor	Julie Strau	<b>b</b>
E &	Group Art Unit		
Sheet TRADENT of 12	Examiner Name		
Sheet MADENTI of 12	Attorney Docket Number	ACU 109 C	P

		OTHER ART - NON PATENT LITERATURE DOCUMENTS							
Examiner's Initials*	Cite No. <sup>1</sup>								
J		SERAJUDDIN, et al., "Water migration from soft gelatin capsule shell to fill material and its effect on drug solubility," J. Pharm. Sci. 75(1):62-64 (1986).							
1		SUZUKI & SUNADA, "Comparison of nicotinamide, ethylurea, and polyethylene glycol as carriers for nifedipine solid dispersion systems," Chem. Pharm. Bull. 45:1688-93 (1997).							
		SUZUKI & SUNADA, "Influence of water-soluble polymers on the dissolution of nifedipine solid dispersions with combined carriers," Chem. Pharm. Bull. 46:482-87 (1998).							
		SWEETANA & AKERS, "Solubility principles and practices for parenteral drug dosage form development," PDA J. Pharm. Sci. Technol. 50(5):330-42 (1996).							
		TAKENAKA, et al., "Preparations of solid particulates of theophylline-ethylenediamine complex by a spray-drying technique," <i>J. Pharm. Sci.</i> 71(8):914-19 (1982).	<u> </u>						
	-	TAKEUCHI, et al., "Enhancement of the dissolution rate of a poorly water-soluble drug (tolbutamide) by a spray-drying solvent deposition method and disintegrants," <i>J. Pharm. Pharmacol.</i> 39(10):769-73 (1987).							
		TASIC, et al., "The influence of beta-cyclodextrin on the solubility and dissolution rate of paracetamol solid dispersions," J. Pharm. Pharmacol. 44(1):52-55 (1992).							
		TINGSTAD, et al., "Dissolution rate studies. III. Effect of type and intensity of agitation on dissolution rate," J. Pharm. Sci. 62(2):293-97 (1973).							
W		TORRADO, et al., "Egg albumin microspheres containing paracetamol for oral administration. I. In vitro characterization," J. Microencapsul. 7(4):463-70 (1990).							
		TRAUE, et al., "Spray products of sparingly soluble-drugs1In-vitro-study-of-spray-products-of-nitrazepam-in-a-starch	•						
		I							

				i
Examiner's	^ ^ -	Date Considered	and.	1 1/
Signature			77	104
			$\neg$	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

### COPY OF PAPERS

				OR	IGINALLY FILED					
Please type a p	ilus sign (+	) inside this box -+	•			Patent and Tr	Approved for use the ademark Office: U.S.	rough 10/31/99	. OMB	98A (10-96 0651-003 DMMERCE
Under the Pape	erwork Rec	fuction Act of 1995	, no persons are required (	lo respond t	o a collection of information unless it co	ntains a valid OMB cont	rol number			
S	Substitut	e for form 1449	9A/PTO			Complete if	Known	RFC	E۱	
a I P	SIA	TEMENT	ON DISCLOS BY APPLIC	THA	Application Number		10/053,929	JUN 2	7 2	2002
NO.	7	(µ <b>s</b> e as many :	sheets as necessary	y)						
1	,	<u> </u>			Filing Date		January 22, 39	PL CENT	ED 4	<del>-</del>
1 HUL	a Mir	۳)			First Named Inventor		Julie Straub-	IT OLIVI	בת ו	<u> - ريانانا</u>
30		ફ્રી			Group Art Unit					
Ž.		3/			Examiner Name	_				
STEED THE	and the	of	12		Attorney Docket Number		ACU 109 CIP			
					NON PATENT LITERATURE					T7
Examiner's Initials*	Cite No.1			ne. jouma	(in CAPITAL LETTERS), title of th I, serial, symposium, catalog, etc.) publisher, city and/or country when	, date, page(s), volu		).		
1		VÉLAZ, et al., "Effect of PEG 4000 on the dissolution rate of naproxen," Eur. J. Drug Metab. Pharmacokinet. 23(2):103-08 (1998).								
10	VENKATARAM & ROGERS, "Characteristics of drug-phospholipid coprecipitates I: Physical properties and dissolution behavior of griseofulvin-dimyristoylphosphatidylcholine systems," J. Pharm. Sci. 73(6):757-61 (1984).									
		'UDATHALA 8 1992).	ROGERS, "Dissol	ution of	fludrocortisone from phosphol	lipid coprecipitates	s," J. Pharm. Sci.	81(3):282	-86	
WAN, et al., "Plasticizers and their effects on microencapsulation process by spray-drying in an aqueous system," J. Microencapsul. 9(1):53-62 (1992).										
					spects of drug release. IV. Tr. J. Pharm. 28:23-31 (1986).	ne effect of carrier	particle propertion	es on the		
1	а	YAMAOKA, et al., "Comparison of body distribution of poly(vinyl alcohol) with other water-soluble polymers after intravenous administration," <i>J. Pharm. Pharmacol.</i> 47:479-86 (1995).								s
T	Y	AMAOKA, et	al., "Fate of water-s	soluble po	olymers administered via diffe	rent routes," J. Pl	harm. Sci. 84(3):	349-54 (199	95).	·
V										
										1

Examiner's Signature	J	Date Considered ${\cal C}$	7	104
			,	(

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.